

Advances in human primordial follicle activation and premature ovarian insufficiency

Emmalee A Ford^{1,2}, Emma L Beckett^{2,3}, Shaun D Roman^{1,2,4}, Eileen A McLaughlin^{1,5,6} and Jessie M Sutherland^{1,2}

¹Priority Research Centre for Reproductive Science, Schools of Biomedical Science & Pharmacy and Environmental & Life Sciences, University of Newcastle, Callaghan, New South Wales, Australia, ²Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia, ³School of Environmental & Life Sciences, Faculty of Science, University of Newcastle, Callaghan, New South Wales, Australia, ⁴Priority Research Centre for Drug Development, University of Newcastle, Callaghan, New South Wales, Australia, ⁵School of Science, Faculty of Science & Technology, University of Canberra, Bruce, Australian Capital Territory, Australia and ⁶School of Biological Sciences, Faculty of Science, University of Auckland, Auckland, New Zealand

Correspondence should be addressed to J M Sutherland; Email: jessie.sutherland@newcastle.edu.au

Abstract

In women, the non-growing population of follicles that comprise the ovarian reserve is determined at birth and serves as the reservoir for future fertility. This reserve of dormant, primordial follicles and the mechanisms controlling their selective activation which constitute the committing step into folliculogenesis are essential for determining fertility outcomes in women. Much of the available data on the mechanisms responsible for primordial follicle activation focuses on a selection of key molecular pathways, studied primarily in animal models, with findings often not synonymous in humans. The excessive induction of primordial follicle activation may cause the development of premature ovarian insufficiency (POI), a condition characterised by menopause before age 40 years. POI affects 1–2% of all women and is accompanied by additional health risks. Therefore, it is critical to further our understanding of primordial follicle activation in order to diagnose, treat and prevent premature infertility. Research in primordial follicle activation has focused on connecting new molecules to already established key signalling pathways, such as phosphatidylinositol 3-Kinase (PI3K) and mammalian target of rapamycin (mTOR). Additionally, other aspects of the ovarian environment, such as the function of the extracellular matrix, in contributing to primordial follicle activation have gained traction. Clinical applications are examining replication of this extracellular environment through the construction of biological matrices mimicking the 3D ovary, to support follicular growth through to ovulation. This review outlines the importance of the events leading to the establishment of the ovarian reserve and highlights the fundamental factors known to influence primordial follicle activation in humans presenting new horizons for female infertility treatment.

Reproduction (2020) **159** R15–R29

Introduction

The total number of immature primordial follicles that reside in a woman's ovaries are established *in utero* from germ cell nests and is termed the ovarian reserve. Moreover, an estimation of a woman's ovarian reserve is considered a fundamental indicator of fertility. Of equal importance to fertility is the rate at which these immature primordial follicles are recruited for growth through a process known as 'activation'. Of these original primordial follicles, numbering between 500,000 and 1,000,000 in total at birth, only approximately 400 will fully mature into primary oocytes capable of being ovulated and fertilised during a woman's reproductive years (Hansen *et al.* 2008, Findlay *et al.* 2015). The overwhelming majority are fated to undergo atresia (ovarian-mediated cell death) (Baker 1963, Tilly 2001, Marcozzi *et al.* 2018).

Primordial follicle activation involves the recruitment of primordial follicles into folliculogenesis for the eventual selection of one oocyte for ovulation. As women age, the pool of primordial follicles, from which to source candidates for activation, plummets. When there are ~1000 primordial follicles remaining, this results in the cessation of fertility and the onset of menopause (Faddy *et al.* 1992, Hansen *et al.* 2008). A key aspect of our understanding of the depletion of the ovarian reserve is that primordial follicles cannot be regenerated or replaced. This concept has been contested by the identification of oogonial stem cells able to produce new oocytes within the mouse ovary, with emerging evidence for their presence in human ovaries (Clarkson *et al.* 2018), but there is still conjecture over a physiological role for these cells based on definitive evidence (reviewed in Horan & Williams 2017).

Thus, the challenge for research is to elucidate the mechanisms controlling the depletion of the ovarian reserve via primordial follicle activation, so that we may provide solutions for those faced with the threat of early fertility loss, such as in the case of premature ovarian insufficiency (POI).

POI may also be referred to as premature ovarian failure, but for the purpose of this review, either term applies interchangeably. POI is an infertility condition diagnosed when menopause occurs prior to the age of 40, due to a significant reduction in, or absence of, a woman's pool of primordial follicles. This condition occurs globally in 1–2% of all women (Coulam *et al.* 1986). POI is defined as the premature cessation or absence of ovarian function and is characterised by amenorrhoea, hypoestrogenism and an increase in gonadotrophin levels (Bachelot *et al.* 2009, Shelling 2010). A common cause of POI is an acceleration in the rate of primordial follicle activation, thereby resulting in a depletion of the ovarian reserve (Nelson 2009). However, the ovarian reserve may also be depleted via primordial follicle loss (Depalo *et al.* 2003) or from iatrogenic causes such as chemotherapeutics (Ben-Aharon & Shalgi 2012). Women often receive a diagnosis of POI when they are already in significant reproductive decline, and as a consequence of their diagnosis may face psychological impacts in addition to the physiological symptoms and infertility of this condition (Van Der Stege *et al.* 2008, Welt 2008). Long-term physical consequences of POI may be severe, even with traditional hormone replacement therapies to ameliorate the negative effects of a loss of ovarian hormonal support. Women with POI have an increased risk of cardiovascular disease, osteoporosis, urogenital atrophy and neurodegenerative disorders (reviewed in Podfigurna-Stopa *et al.* 2016). Thus, it is critical that we continue towards understanding the process of primordial follicle activation as a means of intervention to preserve the ovarian reserve.

Both the establishment of the ovarian reserve and the initial wave of primordial follicle activation occur *in utero*, prior to sexual maturity and gonadotrophic input, thus relying largely upon regulation by intraovarian factors (Lew 2019). Primordial follicle activation dictates the growth and development of the oocyte as well as the differentiation and proliferation of the surrounding somatic granulosa cells, both essential processes for the ultimate goal of ovulation. However, our understanding of the molecular and biochemical processes underpinning follicular activation in humans remains limited. Herein we review the current knowledge and explore future advances towards controlling primordial follicle recruitment and consequently preserving or prolonging female fertility. This is particularly pertinent for those women diagnosed with POI who experience accelerated activation and early depletion of the ovarian reserve.

Early events within the ovary establish the ovarian reserve that sustains fertility

During human embryo sex determination, the primitive gonads are endowed with the primordial germ cells (Tam & Snow 1981) (Fig. 1). The germ cells migrate to the genital ridge of the primitive gonad, then rapidly proliferate until they number 5–6 million (Motta *et al.* 1997, Mamsen *et al.* 2011, Myers *et al.* 2014). This proliferation occurs rapidly and as cytokinesis is not wholly completed, clusters of germ cells (termed germ cell nests) connected via cytoplasmic bridges remain (reviewed by Pepling 2006). Germ cell nest breakdown directly precedes primordial follicle formation and is a major factor influencing the initial size of the ovarian reserve. During this process, pre-granulosa cells (flattened, squamous granulosa cells prior to differentiation into cuboidal granulosa cells) are primed to encapsulate the oocytes via signalling originating from oocytes and intracellular communication between other pre-granulosa cells (De Felici *et al.* 2005, Grive & Freiman 2015, Suzuki *et al.* 2015a). Only a small fraction of the original population of germ cells go on to form primordial follicles, while the remaining oocytes, estimated between one and two thirds, are targeted for coordinated degradation via classical apoptotic mechanisms (Albamonte *et al.* 2008). The role of autophagy in protecting germ cells from apoptosis has been established in mice (Rodrigues *et al.* 2009), with preliminary evidence this occurs in humans too (Sun *et al.* 2017, Zhou *et al.* 2019). The cause for such a substantial loss of oocytes is still unknown, but it is possible that a quality control mechanism exists through which faulty nuclei are lost, and healthy oocytes are preferentially encapsulated into primordial follicles (Tilly 2001, Sun *et al.* 2017). Additionally, a self-sacrifice mechanism previously established in *Drosophila* (de Cuevas *et al.* 1997), and later observed in mice may also be responsible for mammalian germ cell nest breakdown (Grive & Freiman 2015, Pepling 2016). In this mechanism, essential cellular factors are transported via cytoplasmic bridges from neighbouring germ cells within a cluster to the germ cells that will survive and become oocytes in primordial follicles, but this mechanism has not been confirmed in humans (Lei & Spradling 2016).

At the completion of germ cell nest breakdown, the oocytes are each surrounded by a layer of pre-granulosa cells and termed primordial follicles (Maheshwari & Fowler 2008). A surge of retinoic acid released from the mesonephros (primitive kidney) positioned adjacent to the immature ovaries, drives all primordial germ cells to enter meiosis, where they pause arrested at the diplotene stage of prophase I (Borum 1961, Peters 1969). Shortly before birth, primordial follicle activation commences with most follicles developing to the preantral follicle stage (Himelstein-Braw *et al.* 1976). It has been reported that in humans, some follicles will continue onto the antral stage prior to birth (Peters *et al.* 1978).




Figure 1 The development of the human ovarian reserve. The timeline of development of the ovarian reserve is depicted, with representations of the germ cells and somatic cells residing in the ovary, and the stage of life of the female at the point which this occurs. Beginning at 3–5 weeks post conception (wpc) in the embryo, the primordial germ cells migrate to the genital ridge. By 5–16 wpc in the foetus, the primordial germ cells proliferate rapidly and vastly increase in number, resulting in germ cell nests as cytokinesis is not wholly complete. The germ cell nests begin to break down at 17–20 wpc, with many germ cells undergoing apoptosis as the pre-granulosa cells start to encapsulate the germ cells to form primordial follicles. Primordial follicles undergo meiosis after a surge of retinoic acid from the mesonephros, and they remain arrested at prophase I of the cell cycle. From 23–26 wpc the first wave of primordial follicle activation commences, as the oocyte grows and granulosa cells grow and differentiate from their flattened, squamous shape to a cuboidal structure. At around the time of birth at 37–40 wpc, a small proportion of preantral and antral follicles are present. However, until puberty occurs at around 13 years of age, activated follicles can only grow until the early antral stage. At puberty, the input of gonadotrophin allows progression beyond early antral stage through to ovulation.

Increased gonadotrophic production at puberty enables successive follicle growth and ovulation (Dungan *et al.* 2006, Choi & Yoo 2013). Continued activation of primordial follicles occurs dynamically throughout the reproductive years until the onset of menopause. Primordial follicle activation constitutes the committing step into folliculogenesis, as the primordial follicles that are activated throughout a woman's life succumb to one of two fates; to be ovulated or destroyed.

Since the endowment of the ovarian reserve contains the potential for future fertility, and primordial follicle activation is responsible for regulating follicle progression beyond this point, it is important to consider how activation is so precisely controlled so that we may identify those women at risk of accelerated activation and POI and develop practices to preserve or prolong fertility.

Excessive activation of primordial follicles can lead to premature ovarian insufficiency

When the rate of primordial follicle activation is accelerated, and control over the size of the ovarian reserve is lost, POI can result (Kalantaridou *et al.* 1998). POI may be induced by aberrations in other vital ovarian processes which are outside the scope of the current

review, including but not limited to meiosis, DNA repair and gonadotrophin control (Huhtaniemi *et al.* 2018). POI is largely idiopathic (50–70%) (Chapman *et al.* 2015), but known causes include iatrogenic factors (such as chemotherapeutics), genetic factors, environmental factors or autoimmunity. Autoimmunity is responsible for 10–30% of POI cases and is typically related to adrenal disease (Hoek *et al.* 1997, Ebrahimi & Akbari Asbagh 2015). Additional autoimmune diseases that may cause POI include Addison's disease, hypothyroidism, Whitaker syndrome and diabetes mellitus (Conway *et al.* 1996, Ebrahimi & Akbari Asbagh 2015, Komorowska 2016). Yet, the mechanism by which these diseases result in POI is not usually through excessive or uncontrolled primordial follicle activation but through follicular oocyte destruction (Persani *et al.* 2009 for a review). Thus, it is critical that the factors affecting primordial follicle activation be understood in order to identify those at risk of POI early so that fertility can be preserved.

Iatrogenic factors

Amongst the number of iatrogenic factors able to induce POI (radiation, surgery, physical damage to the ovary), it is chemotherapeutics that have been particularly linked

to changes in primordial follicle activation and/or the depletion of the ovarian reserve. Other studies have also linked damage to the vasculature of the ovarian cortex to depletion of primordial follicles (reviewed in Ben-Aharon & Shalgi 2012). In each of these scenarios, patients are at significant risk of developing POI, though it has not yet been confirmed if gonadotoxic treatment is due to accelerated activation or an increase in follicular atresia (Nguyen *et al.* 2019). Typically, chemotherapeutics target proliferating cells and depending on the dose, duration and treatment, granulosa cells are significantly compromised by these treatments, resulting in primordial follicle loss (Abir *et al.* 2008). After treatment with the alkylating agent cyclophosphamide, women have a 40% chance of developing POI, but the cellular mechanisms resulting in premature menopause remain unclear (Cox & Liu 2014). Human ovarian tissue sections cultured in the active metabolites of cyclophosphamide have a decreased primordial follicle population and a concomitant increase in developing follicles (Lande *et al.* 2017). However, in a combined *in vitro* treatment of chemotherapeutics (adriamycin, bleomycin, vinblastine and dacarbazine), the density of non-growing follicles in human ovarian tissue samples was increased (McLaughlin *et al.* 2017).

For women undergoing chemotherapy, fertility preservation through cryopreservation of ovarian tissue, followed by transplantation or assisted reproductive technologies is practised, but further developments to ensure the widespread success of this procedure are still underway (Donnez & Dolmans 2017, Fisch & Abir 2018). New research in mice has identified another chemotherapeutic, dacarbazine, that contributes to primordial follicle depletion (Winship *et al.* 2018), which urges further research into its effect on the ovarian reserve in humans.

Genetic factors

Gene alterations, loss-of-function mutations, and whole chromosomal abnormalities, all demonstrate an ability to alter the rate of primordial follicle activation and thus affect female fertility. Abnormalities of the X chromosome such as deletions, duplications or complete ablation (i.e. Turner syndrome 45XO karyotype) contribute substantially to defects in ovarian development and later problems in fertility (Cordts *et al.* 2011). Some estimates suggest that up to 12% of cases of genetic POI are induced by errors within the X chromosome gene complement (Goswami & Conway 2005, Qin *et al.* 2014). While particular regions on the X chromosome have been identified as vulnerable with regard to the development of ovarian disorders such as POI, it appears that the complex interplay of these genes during folliculogenesis makes it difficult to define one particular causative agent (Chapman *et al.* 2015). Molecular and cytogenetic analyses on the types of genetic abnormalities present

in POI patients have identified a 'critical' region on the long arm of the X chromosome (Xq13-27) that is frequently associated with this disease (reviewed in; Persani *et al.* 2009). Additionally, a number of genes have been associated with POI that regulate primordial follicle recruitment and the gonadotrophin-independent phase of follicular growth (reviewed in Huhtaniemi *et al.* 2018). Several of these have already been established in primordial follicle activation literature as discussed above and include PI3K/AKT/mTOR signalling, FOXL2 and TGF β signalling.

Despite the range of genetic factors known to cause a rapid depletion in available oocytes and the subsequent onset of POI, more genomic interrogation and cellular research is required to reveal the interactions between these factors and determine how they regulate the ovarian reserve through primordial follicle activation.

Environmental factors

Environmental factors with demonstrated impacts on fertility are numerous and are often linked to systemic effects not specifically related to the depletion of the ovarian reserve. However, there are multiple factors that have been directly linked to a decrease in the size of the primordial follicle pool or an increase in the rate of recruitment – both with implications for the development of POI.

Cigarette smoking has the capacity to directly affect the mammalian follicle reserve as evidenced through animal studies (Jurisicova *et al.* 2007, Gannon *et al.* 2012); yet, findings from human studies on primordial follicle populations affected by smoking remain inconsistent (Caserta *et al.* 2013, Peck *et al.* 2016). However, in a cohort of POI patients in Korea, cigarette smoking was strongly associated with an increased risk of the development of POI (Chang *et al.* 2007). In the human fetal ovary, maternal smoke exposure was found to activate aryl hydrocarbon receptor (AHR) and reduce germ cell proliferation, with concomitant implications for germ cell loss via downstream promotion of apoptosis (Mamsen *et al.* 2010, Anderson *et al.* 2014). However, further studies in humans are required to determine if AHR-driven depletion of the primordial follicle pool occurs as a direct result of exposure to cigarette smoke constituents.

Phthalates are toxicants commonly used as plasticising agents and prone to leaching into the environment (Hannon & Flaws 2015). Human fetal ovaries exposed *in vitro* to mono-(2ethylhexyl) phthalate displayed altered lipid synthesis (Muczynski *et al.* 2012). Another phthalate, butyl benzyl phthalate has been demonstrated to decrease the viability of granulosa cells through AHR activation, which, as outlined above, is detrimental to follicular survival rates (Chen *et al.* 2012). These findings suggest ovarian dysfunction that may contribute to a loss in fertility as a consequence of phthalate exposure.

Bisphenol A (BPA) is another mass-produced toxicant that is widely present by virtue of its use in plastics for packaging and resins. BPA affects the ovaries as it has a similar molecular structure to estrogens and can bind to estrogen receptor alpha (Craig *et al.* 2011). Several animal studies have strongly linked BPA exposure to follicle depletion, and this effect is observed regardless of whether exposure occurs *in utero*, postnatally or during adulthood (reviewed in Richardson *et al.* 2014). Consequently, some countries have implemented bans on BPA use based on these animal studies, as human data on the reproductive consequences of BPA remain scarce (Richardson *et al.* 2014, Mathew & Mahalingaiah 2019). Coincidentally, in a study of infertile women, those with higher than average urinary BPA were identified as having a decreased ovarian reserve, and another study explored IVF outcomes for women with higher serum BPA and observed lower pregnancy rates and higher association with miscarriage (Sugiura-Ogasawara *et al.* 2005, Lamb *et al.* 2008).

Cohorts, case studies and genome-wide association studies of POI have been instrumental in our understanding of human primordial follicle activation; yet, there are still substantial gaps in the knowledge of this process. Research is currently being focused towards extrapolating this genomic knowledge into further upstream or downstream influences in the molecular pathways implicated to contribute to the future treatment or even prevention of early depletion of the ovarian reserve.

Humans utilise the classical primordial follicle activation pathways differently

To achieve the preservation of female fertility, the mechanisms that control the size of the ovarian reserve, and the rate of primordial follicle recruitment must be determined. Both these events occur in the absence of gonadotrophic regulation and thus are likely to be wholly reliant on intrinsic signalling mechanisms. The complex network of signalling between the oocytes and the granulosa cells, and between neighbouring granulosa cells is critical in maintaining the size of the ovarian reserve and successive follicle development (Edson *et al.* 2009). Granulosa cells are vital for ensuring the development of the follicle, and their contribution whilst substantial is not yet fully elucidated. The status of granulosa cells is a substantial determinant of follicle survival as follicular atresia can occur if insufficient numbers of granulosa cells surround the oocyte or if these cells do not correctly transition to a cuboidal phenotype upon activation (Gougeon & Chainy 1987, Matsuda *et al.* 2012). There exists considerable literature on the signalling networks and molecules known to be involved in primordial follicle activation in model animal studies (see reviews Adhikari & Liu 2009,

Kim 2012, Zhang & Liu 2015). For most of the factors discussed below, a regulatory role in primordial follicle recruitment was initially established using rodent 'loss-of-function' studies. In humans, an analogous phenotype to rodent studies demonstrating ovarian reserve depletion via accelerated primordial follicle activation is frequently observed in cases of POI (Fig. 2). The current hypothesis of primordial follicle activation in mice follows that mammalian target of rapamycin complex 1 (mTORC1) is activated in the flattened granulosa cells of primordial follicles, and then KIT ligand produced by activated granulosa cells then activates the oocyte via phosphatidylinositol 3-kinase (PI3K) signalling (Zhang *et al.* 2014). However, the model for primordial follicle activation remains unclear. The following section discusses the factors identified as playing a role in human primordial follicle activation and to what extent that role is similar to rodent literature (Table 1).

The PI3K/AKT/mTOR pathway

The phosphatidylinositol 3-kinase/AKT serine/threonine kinase/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is involved in cell survival, growth and migration in various tissues, via the modulation of transcription factors (Cantley 2002). In the mammalian ovary, the PI3K/AKT/mTOR pathway is essential for the regulation of primordial follicle activation, with multiple activators and suppressors identified (reviewed in Zhang & Liu 2015). The negative regulator, phosphatase and tensin homologue deleted on chromosome 10 (PTEN), has been established in human primordial follicle granulosa cells at the protein and gene expression level (Goto *et al.* 2007, Makker *et al.* 2014, Zhang *et al.* 2018). In the ovaries, AKT is a prominent kinase in the PI3K/AKT/mTOR pathway and is expressed in both oocytes and granulosa cells of human follicles (Goto *et al.* 2007, McLaughlin *et al.* 2014). AKT has a wide range of substrates with both direct and indirect roles in follicle activation (Ceconi *et al.* 2012). For women at risk of POI following chemotherapy, primordial follicle activation was stimulated via AKT promotion/PTEN inhibition in ovarian cortical fragments *in vitro* prior to transplantation, and this technique was able to achieve two live births thus far (Kawamura *et al.* 2013, Suzuki *et al.* 2015b, Zhai *et al.* 2016). However, the use of PTEN inhibition to initiate primordial follicle activation has been demonstrated to affect follicular survival (Lerer-Serfaty *et al.* 2013, McLaughlin *et al.* 2014), while in an animal model, prevent DNA repair (Maidarti *et al.* 2019). Thus, this warrants further attention before the technique should be used routinely in human *in vitro* culture pre-transplantation.

The TSC1/mTORC1 subsection of the PI3K/AKT/mTOR pathway was implicated through mouse studies to have a function in driving primordial follicle activation via the differentiation and developmental fates of the




Figure 2 The inhibition and promotion of human primordial follicle activation. Schematics of the factors influencing the maintenance of primordial follicles (the inhibition of primordial follicle activation, PFA) and the activation of primordial follicles (promoting primordial follicle activation). The primordial follicle is activated (right), the oocyte begins to increase in size, and the granulosa cells proliferate and differentiate into a cuboidal morphology. A number of molecules from classical primordial follicle activation pathways established in animal models, like PI3K/PTEN pathway, signal between oocytes and granulosa cells (black arrows indicate stimulation and interaction, blunt end arrow indicates inhibition) through the cell membrane (represented by double lines) where some proteins reside (i.e. SEMA6C and KIT). Additionally, a suite of transcription factors, like NOBOX, and FOXL2 have been established to interact within the nucleus (yellow) affecting the transcription of their target genes. Several factors have been speculated to influence primordial follicle activation (SEMA6C, K8/18), while others have demonstrated effects with no definitive influence (AMH) and these speculative or putative links are indicated by grey, dotted lines.

granulosa cells (Zhang *et al.* 2014), but additional evidence has shown that TSC1 in oocytes is dispensable for primordial follicle activation (Gorre *et al.* 2014). This suggests that mTORC1 is required for primordial follicle activation in the granulosa cells, but not within the oocyte. Within growing mouse oocytes, however, mTORC2 has been demonstrated to be an essential component of follicular development (Chen *et al.* 2015); yet, its role remains uncharacterised in human oocytes. A recent transcriptome study of human follicles identified an upregulation of the pathway's inhibitor *TSC1* in the oocytes of primary follicles when compared to primordial follicles (Zhang *et al.* 2018), which may suggest a similar role in primordial follicle activation, but whether this role functionally redundant as in animal models is yet to be determined. Furthermore, human follicles treated *in vitro* with an mTORC1 inhibitor exhibited a partial reduction in follicle growth and subsequent decrease in *TSC1* mRNA (Grosbois & Demeestere 2018), thus providing supporting evidence for a role in primordial follicle activation.

Despite the PI3K/AKT/mTOR signalling pathways having extensive connections in both primordial follicle activation and the maintenance of quiescence, our

fundamental understanding of these processes is still very limited, particularly in the human. Indeed, there are numerous other cellular mechanisms in addition to this pathway known to be involved in primordial follicle activation, and these include transcription factors, growth factors and cytokines.

Transcription factors

Transcription factors specific to the ovaries also contribute to the regulation of primordial follicle activation. A is a known suppressor of mammalian primordial follicle activation, an inducer of follicle atresia and a known substrate of AKT in the PI3K/AKT/mTOR pathway. Human studies using donor cells and tissue samples from women attending fertility clinics have primarily focused on FOXO3A in ovarian cancer, where it has roles in the apoptosis of follicles through AKT activation (Ding *et al.* 2015), granulosa apoptosis *in vitro* (Ono *et al.* 2014) and tumour progression as a positive regulator of p27 (Fei *et al.* 2009). However, aside from apoptosis in ovarian cancer, a defined role of FOXO3A in primordial follicle activation is lacking from human studies, despite evidence in mice that supports this transcription factor

Table 1 Comparison of factors influencing primordial follicle activation between human and animal models.

Molecule	Species evidence	Role in primordial follicle activation	Cell type gene expressed	Cell type protein localised	References																																																																																							
PI3K	Mouse	Promotes	Oocyte	Oocyte	Adhikari & Liu (2009) Makker <i>et al.</i> (2014), Sun <i>et al.</i> (2015), Zhang <i>et al.</i> (2018)																																																																																							
	Human		Oocyte	Oocyte		PTEN	Mouse	Inhibits	Oocyte	Oocyte	Adhikari & Liu (2009) Goto <i>et al.</i> (2007)	Human	Oocyte	Oocyte	AKT	Mouse	Promotes	Oocyte and granulosa	Oocyte and granulosa	Adhikari & Liu (2009) Goto <i>et al.</i> (2007), McLaughlin <i>et al.</i> (2014), Ernst <i>et al.</i> (2017)	Human	Oocyte	Oocyte and granulosa	FOXO3A	Mouse	Inhibits	Oocytes	Oocyte	Castrillon <i>et al.</i> (2003), John <i>et al.</i> (2008)	mTORC1	Human	Unknown	Unknown	Unknown	Tarnawa <i>et al.</i> (2013) Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Ernst <i>et al.</i> (2017), Ernst <i>et al.</i> (2018)	Mouse	Promotes	Oocyte and granulosa	Oocyte and granulosa	mTORC2	Mouse	Promotes	Oocyte	Oocyte	Chen <i>et al.</i> (2015)	Human	Unknown	Unknown	Unknown	TSC1	Mouse	Inhibits	Oocyte and granulosa	Oocyte and granulosa	Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Grosbois & Demeestere (2018), Zhang <i>et al.</i> (2018)	Human	Not specified	Not specified	LHX8	Mouse	Inhibits	Oocyte	Oocyte	Pangas <i>et al.</i> (2006), Ren <i>et al.</i> (2015) Kristensen <i>et al.</i> (2015)	Human	Oocyte	Not specified	AMH	Rat and mouse	Inhibits	Granulosa	Granulosa	Baarends <i>et al.</i> (1995), Durlinger <i>et al.</i> (2002) Schmidt <i>et al.</i> (2005), Carlsson <i>et al.</i> (2006)	Human	Unknown	Granulosa	Granulosa	BMP-4	Mouse	Promotes	Granulosa and oocyte	granulosa and oocyte	Chang <i>et al.</i> (2002), Knight & Glister (2006) Ikeda <i>et al.</i> (2016), Pierre <i>et al.</i> (2016)	Human	Granulosa	Oocyte and Granulosa	BMP-15	Mouse	Promotes	Oocyte and granulosa	Oocyte and Granulosa	Chang <i>et al.</i> (2002), Knight & Glister (2006), Persani <i>et al.</i> (2014) Margulis <i>et al.</i> (2009), Manavella <i>et al.</i> (2019)
PTEN	Mouse	Inhibits	Oocyte	Oocyte	Adhikari & Liu (2009) Goto <i>et al.</i> (2007)																																																																																							
	Human		Oocyte	Oocyte		AKT	Mouse	Promotes	Oocyte and granulosa	Oocyte and granulosa	Adhikari & Liu (2009) Goto <i>et al.</i> (2007), McLaughlin <i>et al.</i> (2014), Ernst <i>et al.</i> (2017)	Human	Oocyte	Oocyte and granulosa	FOXO3A	Mouse	Inhibits	Oocytes	Oocyte	Castrillon <i>et al.</i> (2003), John <i>et al.</i> (2008)	mTORC1	Human	Unknown	Unknown	Unknown	Tarnawa <i>et al.</i> (2013) Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Ernst <i>et al.</i> (2017), Ernst <i>et al.</i> (2018)	Mouse	Promotes	Oocyte and granulosa	Oocyte and granulosa	mTORC2	Mouse	Promotes	Oocyte	Oocyte	Chen <i>et al.</i> (2015)	Human	Unknown	Unknown	Unknown	TSC1	Mouse	Inhibits	Oocyte and granulosa	Oocyte and granulosa	Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Grosbois & Demeestere (2018), Zhang <i>et al.</i> (2018)	Human	Not specified	Not specified	LHX8	Mouse	Inhibits	Oocyte	Oocyte	Pangas <i>et al.</i> (2006), Ren <i>et al.</i> (2015) Kristensen <i>et al.</i> (2015)	Human	Oocyte	Not specified	AMH	Rat and mouse	Inhibits	Granulosa	Granulosa	Baarends <i>et al.</i> (1995), Durlinger <i>et al.</i> (2002) Schmidt <i>et al.</i> (2005), Carlsson <i>et al.</i> (2006)	Human	Unknown	Granulosa	Granulosa	BMP-4	Mouse	Promotes	Granulosa and oocyte	granulosa and oocyte	Chang <i>et al.</i> (2002), Knight & Glister (2006) Ikeda <i>et al.</i> (2016), Pierre <i>et al.</i> (2016)	Human	Granulosa	Oocyte and Granulosa	BMP-15	Mouse	Promotes	Oocyte and granulosa	Oocyte and Granulosa	Chang <i>et al.</i> (2002), Knight & Glister (2006), Persani <i>et al.</i> (2014) Margulis <i>et al.</i> (2009), Manavella <i>et al.</i> (2019)	Human	Oocyte and granulosa	Oocyte and granulosa						
AKT	Mouse	Promotes	Oocyte and granulosa	Oocyte and granulosa	Adhikari & Liu (2009) Goto <i>et al.</i> (2007), McLaughlin <i>et al.</i> (2014), Ernst <i>et al.</i> (2017)																																																																																							
	Human		Oocyte	Oocyte and granulosa		FOXO3A	Mouse	Inhibits	Oocytes	Oocyte	Castrillon <i>et al.</i> (2003), John <i>et al.</i> (2008)	mTORC1	Human	Unknown	Unknown	Unknown	Tarnawa <i>et al.</i> (2013) Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Ernst <i>et al.</i> (2017), Ernst <i>et al.</i> (2018)	Mouse	Promotes	Oocyte and granulosa	Oocyte and granulosa	mTORC2	Mouse	Promotes	Oocyte	Oocyte	Chen <i>et al.</i> (2015)	Human	Unknown	Unknown	Unknown	TSC1	Mouse	Inhibits	Oocyte and granulosa	Oocyte and granulosa	Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Grosbois & Demeestere (2018), Zhang <i>et al.</i> (2018)	Human	Not specified	Not specified	LHX8	Mouse	Inhibits	Oocyte	Oocyte	Pangas <i>et al.</i> (2006), Ren <i>et al.</i> (2015) Kristensen <i>et al.</i> (2015)	Human	Oocyte	Not specified	AMH	Rat and mouse	Inhibits	Granulosa	Granulosa	Baarends <i>et al.</i> (1995), Durlinger <i>et al.</i> (2002) Schmidt <i>et al.</i> (2005), Carlsson <i>et al.</i> (2006)	Human	Unknown	Granulosa	Granulosa	BMP-4	Mouse	Promotes	Granulosa and oocyte	granulosa and oocyte	Chang <i>et al.</i> (2002), Knight & Glister (2006) Ikeda <i>et al.</i> (2016), Pierre <i>et al.</i> (2016)	Human	Granulosa	Oocyte and Granulosa	BMP-15	Mouse	Promotes	Oocyte and granulosa	Oocyte and Granulosa	Chang <i>et al.</i> (2002), Knight & Glister (2006), Persani <i>et al.</i> (2014) Margulis <i>et al.</i> (2009), Manavella <i>et al.</i> (2019)	Human	Oocyte and granulosa	Oocyte and granulosa															
FOXO3A	Mouse	Inhibits	Oocytes	Oocyte	Castrillon <i>et al.</i> (2003), John <i>et al.</i> (2008)																																																																																							
mTORC1	Human	Unknown	Unknown	Unknown	Tarnawa <i>et al.</i> (2013) Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Ernst <i>et al.</i> (2017), Ernst <i>et al.</i> (2018)																																																																																							
	Mouse	Promotes	Oocyte and granulosa	Oocyte and granulosa																																																																																								
mTORC2	Mouse	Promotes	Oocyte	Oocyte	Chen <i>et al.</i> (2015)																																																																																							
	Human	Unknown	Unknown	Unknown																																																																																								
TSC1	Mouse	Inhibits	Oocyte and granulosa	Oocyte and granulosa	Gorre <i>et al.</i> (2014), Zhang <i>et al.</i> (2014) Grosbois & Demeestere (2018), Zhang <i>et al.</i> (2018)																																																																																							
	Human		Not specified	Not specified																																																																																								
LHX8	Mouse	Inhibits	Oocyte	Oocyte	Pangas <i>et al.</i> (2006), Ren <i>et al.</i> (2015) Kristensen <i>et al.</i> (2015)																																																																																							
	Human		Oocyte	Not specified																																																																																								
AMH	Rat and mouse	Inhibits	Granulosa	Granulosa	Baarends <i>et al.</i> (1995), Durlinger <i>et al.</i> (2002) Schmidt <i>et al.</i> (2005), Carlsson <i>et al.</i> (2006)																																																																																							
	Human	Unknown	Granulosa	Granulosa																																																																																								
BMP-4	Mouse	Promotes	Granulosa and oocyte	granulosa and oocyte	Chang <i>et al.</i> (2002), Knight & Glister (2006) Ikeda <i>et al.</i> (2016), Pierre <i>et al.</i> (2016)																																																																																							
	Human		Granulosa	Oocyte and Granulosa																																																																																								
BMP-15	Mouse	Promotes	Oocyte and granulosa	Oocyte and Granulosa	Chang <i>et al.</i> (2002), Knight & Glister (2006), Persani <i>et al.</i> (2014) Margulis <i>et al.</i> (2009), Manavella <i>et al.</i> (2019)																																																																																							
	Human		Oocyte and granulosa	Oocyte and granulosa																																																																																								

as a key molecular regulator (Castrillon *et al.* 2003, John *et al.* 2008, Chang *et al.* 2015). While a few *FOXO3A* mutations have been identified in POI patients, the causative contribution these mutations may have on the condition requires investigation (Watkins *et al.* 2006), especially considering *FOXO3A* is not expressed in human primordial oocytes, unlike its mouse counterpart (Tarnawa *et al.* 2013). Thus, it is unlikely that *FOXO3A* maintains the quiescence of primordial follicles in humans as in mice.

The transcription factor Forkhead box L2 (*FOXL2*) is essential for squamous to cuboidal granulosa cell differentiation and subsequent formation of secondary follicles in animal models (Schmidt *et al.* 2004, Uda *et al.* 2004, Uhlenhaut & Treier 2006). Many studies in human cell lines, and in mice, have reported *FOXL2* targets are also involved in apoptosis, differentiation and

the cell cycle (as reviewed in Georges *et al.* 2014), further demonstrating the critical functions of this transcription factor. Notably, a study of human granulosa cells demonstrated that *FOXL2* transcripts were less abundant in granulosa cells from primary follicles compared to granulosa cells from primordial follicles (Ernst *et al.* 2018), providing preliminary evidence that *FOXL2* downregulation between these stages may coincide with a role in primordial follicle activation in humans. Further investigation of the role of this transcription factor in primordial follicle activation is warranted to confirm the role of *FOXL2* in human primordial follicles.

A binding partner of *FOXL2* is *NOBOX*, which is involved in folliculogenesis and the regulation of oocyte-specific gene expression (Huntriss *et al.* 2006, Bouilly *et al.* 2014). In mice, *NOBOX* is critical for early ovarian development and indirectly participates in

primordial follicle activation via its transcriptional targets (Rajkovic *et al.* 2004, Lechowska *et al.* 2011). Recently, NOBOX transcriptional targets in both humans and mice have been identified and include essential oocyte developmental factors such as growth differentiation factor 9 (GDF9) and octamer-binding transcription factor 4 (OCT4) (Choi & Rajkovic 2006, Bayne *et al.* 2015). Additionally, a novel, loss-of-function *NOBOX* mutation was identified in a POI patient (Li *et al.* 2017), providing further evidence of a key role for this gene in primordial follicle activation. These existing studies justify further investigation of the role that NOBOX has in human primordial follicles.

The LIM homeobox 8 (LHX8) transcription factor has long been associated with the suppression of mouse primordial follicle activation by blocking the expression of RNA-binding protein LIN28A, an upstream activator of the PI3K/AKT/mTOR pathway (Pangas *et al.* 2006, Ren *et al.* 2015). In humans, *Lhx8* transcripts were reported to have decreased expression in early primary follicle oocytes compared to primordial follicle oocytes, thus suggesting a role in the primordial to primary transition (Kristensen *et al.* 2015). This finding highlights the importance of identifying the extent of the roles of currently established pathways in primordial follicle activation.

Growth factors of the TGF β superfamily

The TGF β family of growth factors are involved in a range of cellular processes throughout the body, but in the ovaries specifically, they have roles in early ovarian development and follicle growth (Drummond 2005). Anti-Mullerian-inhibiting substance (AMH) is known, via animal models, to be expressed in the growing follicles, localising specifically to the granulosa cells, and has been established as a suppressor of primordial follicle activation (Visser & Themmen 2005). Corroborating studies in human ovaries have shown that when cultured *in vitro*, AMH could inhibit the proportion of primordial follicles being activated (Carlsson *et al.* 2006). However, conflicting evidence from a 4-week culture of human ovarian tissue supplemented with AMH demonstrated that significantly more follicles were activated to enter the growing phase (Schmidt *et al.* 2005). The mechanisms behind AMH's effect on the ovarian reserve remain unclear as even rodent primordial follicles do not express AMH receptors (Baarends *et al.* 1995, Durlinger *et al.* 2002). In mice, it has been established that *Amh* is a transcriptional target of FOXL2, and thus suggesting they operate in conjunction to maintain the ovarian reserve of primordial follicles (Park *et al.* 2014). Recent evidence in humans has identified that FOXL2 controls AMH indirectly through the transcriptional activation of steroidogenic factor-1, which is a regulator of AMH (Jin *et al.* 2016). Further research has established an inverse relationship whereby AMH is able to modulate

the amount of FOXL2 in human granulosa cells (Sacchi *et al.* 2017).

Bone morphogenetic proteins (BMPs) 4 and 15 may participate in early-stage folliculogenesis in humans, in line with several animal studies (see reviews Chang *et al.* 2002, Knight & Glister 2006, Persani *et al.* 2014). Preliminary studies in human gonadal cell culture models have identified BMP4 activity in both the somatic and germ cells during the establishment of the ovarian reserve via the promotion of primordial germ cell apoptosis and the differentiation of pre-granulosa cells (Childs *et al.* 2010, Bayne *et al.* 2016). Studies have also identified the involvement of BMP4 in facilitating the primordial to primary follicle transition in both mouse (Ding *et al.* 2013) and human ovary culture (Ikeda *et al.* 2016). *In vitro* treatment of cultured human GCs with BMP4 and/or 15 induced AMHR2 gene expression (Pierre *et al.* 2016) and this work built on that in sheep models (Estienne *et al.* 2015).

This section has provided an overview of the critical pathways, transcriptional regulators and growth factors that contribute to either the maintenance of the primordial follicle reserve or its activation and subsequent depletion in humans. Many of the factors traditionally associated with primordial follicle activation research have been studied extensively in rodent model systems, with a large portion as yet unstudied in humans or contributing inconsistencies between species. These contrasting studies highlight the importance of continued research in this field to determine if current animal-based research is consistent in humans or warrants the development of more suitable models.

Current research into primordial follicle activation

New insights into primordial follicle activation have arisen primarily from transcriptomic studies, in addition to conditional expression and knockdown studies in animals. Within this research, new factors are identified that link to already established pathways and events. Attention is also being focused towards how intraovarian factors derived from the granulosa cells and the extracellular matrix contribute to the activation status of the follicle.

A family of histone deacetylases, sirtuins, maintain homeostasis throughout the body, responding to changes in metabolism, inflammation and ageing (Vachharajani *et al.* 2016, Grabowska *et al.* 2017). Early work identified that sirtuin 1-null mice were infertile, with no exposition of the underpinning mechanism (McBurney *et al.* 2003). The presence of sirtuins (SIRTs) has been confirmed in the ovaries of humans, including in the oocyte and granulosa cells, with little evidence, as yet, of their function and how they may contribute to the maintenance of the ovarian reserve or folliculogenesis (Tatone *et al.* 2018). However, SIRTs have recently been linked to the mTOR signalling pathway in rat ovaries,

capable of targeting the activation inhibitor FOXO3a in order to control primordial follicle activation in response to environmental cues like nutrient status (reviewed in [Tatone et al. 2018](#)). An upstream regulator of the PI3K/AKT/mTOR pathway, Semaphorin 6C (SEMA6C) ([Fig. 2](#)), has been newly identified to suppress primordial follicle activation in mice ([Zhou et al. 2018](#)). Semaphorins were traditionally characterised in the brain, but after links to extensive biological functions in other tissues, they were also found to be functional in human ovaries ([Borgbo et al. 2013](#)).

A recent study of the transcriptome of human primordial and primary follicles has revealed some novel proteins that may be associated with this developmental transition. Notably, an additional Forkhead transcription factor, *FOXO1*, which exhibited a transcriptional decrease during the primordial to primary transition ([Ernst et al. 2017](#)). This decrease was accompanied by a subsequent relocation of FOXO1 protein from the oocyte nucleus to cytoplasm indicating a similar role to the well-established function of FOXO3A. Members of the eukaryotic translation initiation factor 2 (EIF2) signalling pathway were also identified to be upregulated during the primordial to primary transition. In particular, the EIF4E gene was observed to increase at the transcript and protein level ([Ernst et al. 2017](#)). EIF4E traditionally facilitates the translation of stored mRNA in oocytes ([Henderson et al. 2009](#)).

There has also been growing interest in the TATA-binding proteins (TBPs) and the oocyte-specific TBP2. Emerging evidence in mice has identified the ontogeny of the expression patterns of this protein, which suggests it has a role in the primordial to primary transition – contributing to transcription status of the follicle ([Schultz et al. 2018](#)). However, studies in human POI cohorts reveal conflicting data, with overexpression observed in some cases, and other studies contend that TBPs do not contribute to POI ([Tsuiko et al. 2016](#), [Wang et al. 2016](#)). A new potential marker of primordial follicles about to undergo activation is the expression status of keratin. The presence of the keratin 8/18 heterodimer (K8/K18) in granulosa cells was strongly correlated with survival status in addition to granulosa cells undergoing the squamous to cuboidal transition ([Gaytan et al. 2018](#)). Indeed, transcriptional silencing of K8/K18 using siRNA interference in human granulosa cell-like KGNs induced apoptosis ([Trisdale et al. 2016](#)). This evidence, while still in preliminary stages, prompts further investigation into the role of K8/18, and other typically epithelial-related proteins in granulosa cell physiology. Insulin-like growth factors (IGFs) are traditionally connected to proliferation and antiapoptotic signalling pathways in the ovaries (reviewed in [Amutha & Rajkumar 2017](#)) and have now been demonstrated to promote follicle growth via the PI3K/AKT/mTOR pathway in sheep ([Bezerra et al. 2018](#)), with further evidence demonstrating that transcripts from members of IGF1 signalling were differently

expressed in human primordial and primary granulosa cells ([Ernst et al. 2017](#), [Steffensen et al. 2018](#)). The cause for differential IGF1 expression between these two cell stages requires further investigation to determine if IGF1 expression is indeed linked to the activation of primordial follicles. However, the role of IGFs and whether they can modulate activation *in vivo* through androgens or PI3K signalling is yet to be validated.

The extracellular matrix within the ovary is known to be essential for granulosa cell survival and proliferation, and as such is an important consideration in ovarian developmental abnormalities ([Berkholtz et al. 2006](#)). An appropriately rigid ovarian extracellular environment may be a necessary requirement for follicle survival and has been implicated in the induction of conditions such as POI via the loss of factors essential for maintaining stromal thickness, like FOXL2 ([Woodruff & Shea 2011](#)). A recent finding in cat ovarian studies has identified a potential link to primordial follicle activation within a group of extracellular matrix enzymes, the matrix metalloproteinases (MMPs) ([Fujihara et al. 2018](#)). The activity of MMP9 was stimulated *in vitro* via a high dose of retinoic acid, which led to an increase in the number of follicles undergoing primordial follicle activation ([Fujihara et al. 2018](#)). Indeed, other growth factors involved in primordial follicle activation (including TGF β superfamily members) are capable of binding to ECM components ([Smith et al. 1999](#)), and thus, the availability of these growth factors may be able to be regulated by the extracellular matrix and ensure the survival of primordial follicles. Recent evidence in the mouse has linked the expression of other TGF β signalling pathway members, the downstream SMAD2/3, to the inhibition of primordial follicle activation by preventing granulosa cell proliferation ([Hardy et al. 2018](#)). While current laboratory research is focused on dissecting primordial follicle activation pathways, in clinical research, the challenges lie in diagnostics and controlling the growth and maturation of captured primordial follicles.

Future clinical directions towards harnessing the primordial follicle

By understanding the factors controlling primordial follicle recruitment, we aim to provide POI patients with targeted intervention to prolong their reproductive lifespan. The development and validation of markers and tests that will enable practitioners to identify at risk women are crucial, and with new advancements in technology, there is hope for novel diagnostics and treatments in the coming decades. The technique of optical coherence tomography imaging, used commonly in ophthalmology, was utilised to assess accurately (when compared to histological controls) cortical ovarian tissue sections of chemotherapy patients ([Wang et al. 2015](#)), indicating its future potential as a non-invasive method for primordial follicle assessment.

A technique for the preservation of fertility still regarded as experimental, but used by clinicians nonetheless, particularly in patients undergoing chemotherapeutic treatment or who have a reduced ovarian reserve, is the surgical removal of small fragment(s) of the ovarian cortex, where primordial follicles reside (Oktay *et al.* 1997, McLaughlin *et al.* 2015). Intact whole ovaries can also be removed and preserved to excise fragments for later use (Gellert *et al.* 2018). Fragments can be cryopreserved until such time that they are transplanted back into the patient, with follicle activation stimulated *in vivo* (post transplantation), and this strategy has now been successful in producing over 130 live births (Demeestere *et al.* 2015, Donnez & Dolmans 2017, Shapira *et al.* 2018). However, the revascularisation of this transplanted cortical tissue remains a limiting factor in treating infertility. Despite these limitations, promising evidence has emerged through the use of engineered endothelial cells expressing AMH. In a mouse model, the co-transplantation of these engineered epithelial cells with cryopreserved tissue has revealed both the promotion of quiescence in primordial follicles and increased perfusion (Man *et al.* 2018). Alternate efforts to promote angiogenesis of transplanted human ovarian tissue using a mouse model has also been achieved via the assistance of adipose tissue-derived stem cells. The adipose-derived stem cells were preseeded onto the grafting site prior to transplantation of human ovarian tissue and were able to differentiate into human blood vessels and support ovarian survival (Manavella *et al.* 2019).

Ovarian cortical tissue fragments may also be used to grow follicles *in vitro* via an 'artificial ovary' – typically a biological matrix of materials like fibrin, collagen and alginate (Telfer & Fauser 2016, Kallen *et al.* 2018). These models are able to elicit patterns of hormonal fluctuations and growth of human follicles to the antral stage in a manner closely resembling those observed *in vivo* (Skory *et al.* 2015). Ovarian cortical tissue fragments can be directly placed within the matrix and cultured to grow mature follicles (Laronda *et al.* 2014). Primordial follicles can also be isolated from the tissue before being placed in the artificial ovary for activation; they may also be activated *in vitro* prior to being placed in the matrix (McLaughlin *et al.* 2011, Chiti *et al.* 2017). Alternatively, primary or secondary follicles can be removed from the tissue fragment and cultured successfully in a hydrogel matrix, with ovulation observed in mice, and a small number of meiotically competent metaphase II stage oocytes achieved in human follicles after IVM (Skory *et al.* 2015, Xiao *et al.* 2015). While these methods are still in early development, it is hoped that they will maximise the survival and retention of primordial follicles obtained from patients for future *in vitro* maturation and subsequent IVF.

Despite these novel developments, the fact remains that *in vitro* control over the activation of primordial

follicles and future developmental competency is yet to be realised in human oocytes, and this is fundamentally linked to our limited understanding of the process of primordial follicle activation. Ovarian cortical tissue culture usually leads to mass spontaneous, uncontrolled primordial follicle activation, and thus future challenges lie in advancing the culture media and 3D support structures to include the necessary inhibitors to allow the timing of activation to occur in an appropriate and controlled manner (reviewed in Bertoldo *et al.* 2018). This mass activation that occurs *in vitro* has recently been tied to disruptions in Hippo signalling caused by cortex fragmentation, specifically by the movement of Hippo pathway effector, yes-associated protein (YAP), into the nucleus of granulosa cells in humans and mice. The translocation of YAP subsequently introduced growth factors and apoptosis inhibitors, which resulted in follicle growth, indicating a positive influence on primordial follicle activation (Grosbois & Demeestere 2018). This activity was subsequently found to be mediated via AKT of the PI3K/AKT/mTOR pathway (Hu *et al.* 2019), thus demonstrating roles for Hippo-yap signalling in regulating primordial follicle activation, and new potential targets for future drug developments *in vitro* fertility preservation.

Conclusion

The committing step of primordial follicle activation and the regulated depletion of the ovarian reserve remain barriers to current attempts to preserve fertility, particularly in cases of POI. Previous studies have focused on dissecting intraovarian pathways involved in the growth and differentiation of the follicle. However, the reliance on animal models has resulted in some limitations, with findings in human studies not always synonymous. While the aetiology of POI is complex and inducible by internal and external factors, future research into controlling the rate of activation may provide strategies for early diagnosis or prevention. The clinical need for solutions to maintain the primordial follicle pool, particularly in cases where girls and young women must undergo chemotherapy, requires a greater focus in human studies, coupled with the development of robust modelling systems such as those discussed in this review. Enhancing the knowledge of primordial follicle activation, and the factors that facilitate the entry to this process will not only improve outcomes for those at risk of premature fertility loss but may provide the key to preventing these conditions altogether.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.

Funding

This project has been funded by the Australian National Health and Medical Research Council (G1600095) and the Hunter Medical Research Institute Bob and Terry Kennedy Children's Research Project Grant in Pregnancy & Reproduction (G1501433 and G1801335).

Acknowledgements

The authors would like to acknowledge the contributions of Dr Elizabeth Bromfield for revising the manuscript critically for important intellectual content. The authors gratefully acknowledge the financial assistance to E A F and J M S by the Australian National Health and Medical Research Council, the Hunter Medical Research Institute, and the University of Newcastle.

References

- Abir R, Ben-Haroush A, Felz C, Okon E, Raanani H, Orvieto R, Nitke S & Fisch B 2008 Selection of patients before and after anticancer treatment for ovarian cryopreservation. *Human Reproduction* **23** 869–877. (<https://doi.org/10.1093/humrep/dem413>)
- Adhikari D & Liu K 2009 Molecular mechanisms underlying the activation of mammalian primordial follicles. *Endocrine Reviews* **30** 438–464. (<https://doi.org/10.1210/er.2008-0048>)
- Albamonte MS, Willis MA, Albamonte MI, Jensen F, Espinosa MB & Vitullo AD 2008 The developing human ovary: immunohistochemical analysis of germ-cell-specific vasa protein, BCL-2/BAX expression balance and apoptosis. *Human Reproduction* **23** 1895–1901. (<https://doi.org/10.1093/humrep/den197>)
- Amutha P & Rajkumar T 2017 Role of insulin-like growth factor, insulin-like growth factor receptors, and insulin-like growth factor-binding proteins in ovarian cancer. *Indian Journal of Medical and Paediatric Oncology* **38** 198–206. (https://doi.org/10.4103/ijmpo.ijmpo_3_17)
- Anderson RA, McIlwain L, Coutts S, Kinnell HL, Fowler PA & Childs AJ 2014 Activation of the aryl hydrocarbon receptor by a component of cigarette smoke reduces germ cell proliferation in the human fetal ovary. *Molecular Human Reproduction* **20** 42–48. (<https://doi.org/10.1093/molehr/gat059>)
- Baarends WM, Uilenbroek JT, Kramer P, Hoogerbrugge JW, Van Leeuwen EC, Themmen AP & Grootegoed JA 1995 Anti-Müllerian hormone and anti-Müllerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. *Endocrinology* **136** 4951–4962. (<https://doi.org/10.1210/endo.136.11.7588229>)
- Bachelot A, Rouxel A, Massin N, Dulon J, Courtillot C, Matuchansky C, Badachi Y, Fortin A, Paniel B, Lecuru F *et al.* 2009 Phenotyping and genetic studies of 357 consecutive patients presenting with premature ovarian failure. *European Journal of Endocrinology* **161** 179–187. (<https://doi.org/10.1530/EJE-09-0231>)
- Baker TG 1963 A quantitative and cytological study of germ cells in human ovaries. *Proceedings of the Royal Society of London: Series B, Biological Sciences* **158** 417–433. (<https://doi.org/10.1098/rspb.1963.0055>)
- Bayne RA, Kinnell HL, Coutts SM, He J, Childs AJ & Anderson RA 2015 GDF9 is transiently expressed in oocytes before follicle formation in the human fetal ovary and is regulated by a novel NOBOX transcript. *PLoS ONE* **10** e0119819. (<https://doi.org/10.1371/journal.pone.0119819>)
- Bayne RA, Donnachie DJ, Kinnell HL, Childs AJ & Anderson RA 2016 BMP signalling in human fetal ovary somatic cells is modulated in a gene-specific fashion by GREM1 and GREM2. *Molecular Human Reproduction* **22** 622–633. (<https://doi.org/10.1093/molehr/gaw044>)
- Ben-Aharon I & Shalgi R 2012 What lies behind chemotherapy-induced ovarian toxicity? *Reproduction* **144** 153–163. (<https://doi.org/10.1530/REP-12-0121>)
- Berkholtz CB, Shea LD & Woodruff TK 2006 Extracellular matrix functions in follicle maturation. *Seminars in Reproductive Medicine* **24** 262–269. (<https://doi.org/10.1055/s-2006-948555>)
- Bertoldo MJ, Walters KA, Ledger WL, Gilchrist RB, Mermillod P & Locatelli Y 2018 In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies. *Reproductive Biomedicine Online* **36** 491–499. (<https://doi.org/10.1016/j.rbmo.2018.01.014>)
- Bezerra MÉS, Barberino RS, Menezes VG, Gouveia BB, Macedo TJS, Santos JMS, Monte APO, Barros VRP & Matos MHT 2018 Insulin-like growth factor-1 (IGF-1) promotes primordial follicle growth and reduces DNA fragmentation through the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) signalling pathway. *Reproduction, Fertility, and Development* **30** 1503–1513. (<https://doi.org/10.1071/RD17332>)
- Borgbo T, Povlsen BB, Andersen CY, Borup R, Humaidan P & Grondahl ML 2013 Comparison of gene expression profiles in granulosa and cumulus cells after ovulation induction with either human chorionic gonadotropin or a gonadotropin-releasing hormone agonist trigger. *Fertility and Sterility* **100** 994–1001. (<https://doi.org/10.1016/j.fertnstert.2013.05.038>)
- Borum K 1961 Oogenesis in the mouse. A study of the meiotic prophase. *Experimental Cell Research* **24** 495–507. ([https://doi.org/10.1016/0014-4827\(61\)90449-9](https://doi.org/10.1016/0014-4827(61)90449-9))
- Bouilly J, Veitia RA & Binart N 2014 NOBOX is a key FOXL2 partner involved in ovarian folliculogenesis. *Journal of Molecular Cell Biology* **6** 175–177. (<https://doi.org/10.1093/jmcb/mju006>)
- Cantley LC 2002 The phosphoinositide 3-kinase pathway. *Science* **296** 1655–1657. (<https://doi.org/10.1126/science.296.5573.1655>)
- Carlsson IB, Scott JE, Visser JA, Ritvos O, Themmen AP & Hovatta O 2006 Anti-Müllerian hormone inhibits initiation of growth of human primordial ovarian follicles in vitro. *Human Reproduction* **21** 2223–2227. (<https://doi.org/10.1093/humrep/del165>)
- Caserta D, Bordi G, Di Segni N, D'ambrosio A, Mallozzi M & Moscarini M 2013 The influence of cigarette smoking on a population of infertile men and women. *Archives of Gynecology and Obstetrics* **287** 813–818. (<https://doi.org/10.1007/s00404-012-2643-5>)
- Castrillon DH, Miao L, Kollipara R, Horner JW & Depinho RA 2003 Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. *Science* **301** 215–218. (<https://doi.org/10.1126/science.1086336>)
- Cecconi S, Mauro A, Cellini V & Patacchiola F 2012 The role of Akt signalling in the mammalian ovary. *International Journal of Developmental Biology* **56** 809–817. (<https://doi.org/10.1387/ijdb.120146sc>)
- Chang H, Brown CW & Matzuk MM 2002 Genetic analysis of the mammalian transforming growth factor- β superfamily. *Endocrine Reviews* **23** 787–823. (<https://doi.org/10.1210/er.2002-0003>)
- Chang SH, Kim CS, Lee KS, Kim H, Yim SV, Lim YJ & Park SK 2007 Premenopausal factors influencing premature ovarian failure and early menopause. *Maturitas* **58** 19–30. (<https://doi.org/10.1016/j.maturitas.2007.04.001>)
- Chang EM, Lim E, Yoon S, Jeong K, Bae S, Lee DR, Yoon TK, Choi Y & Lee WS 2015 Cisplatin induces overactivation of the dormant primordial follicle through PTEN/AKT/FOXO3a pathway which leads to loss of ovarian reserve in mice. *PLoS ONE* **10** e0144245. (<https://doi.org/10.1371/journal.pone.0144245>)
- Chapman C, Cree L & Shelling AN 2015 The genetics of premature ovarian failure: current perspectives. *International Journal of Women's Health* **7** 799–810. (<https://doi.org/10.2147/IJWH.S64024>)
- Chen HS, Chiang PH, Wang YC, Kao MC, Shieh TH, Tsai CF & Tsai EM 2012 Benzyl butyl phthalate induces necrosis by AhR mediation of CYP1B1 expression in human granulosa cells. *Reproductive Toxicology* **33** 67–75. (<https://doi.org/10.1016/j.reprotox.2011.11.004>)
- Chen Z, Kang X, Wang L, Dong H, Wang C, Xiong Z, Zhao W, Jia C, Lin J, Zhang W *et al.* 2015 Rictor/mTORC2 pathway in oocytes regulates folliculogenesis, and its inactivation causes premature ovarian failure. *Journal of Biological Chemistry* **290** 6387–6396. (<https://doi.org/10.1074/jbc.M114.605261>)
- Childs AJ, Kinnell HL, Collins CS, Hogg K, Bayne RA, Green SJ, McNeilly AS & Anderson RA 2010 BMP signalling in the human fetal ovary is developmentally regulated and promotes primordial germ cell apoptosis. *Stem Cells* **28** 1368–1378. (<https://doi.org/10.1002/stem.440>)
- Chiti MC, Dolmans MM, Hobeika M, Cernogoraz A, Donnez J & Amorim CA 2017 A modified and tailored human follicle isolation procedure improves follicle recovery and survival. *Journal of Ovarian Research* **10** 71. (<https://doi.org/10.1186/s13048-017-0366-8>)
- Choi Y & Rajkovic A 2006 Characterization of NOBOX DNA binding specificity and its regulation of Gdf9 and Pou5f1 promoters.

- Journal of Biological Chemistry* **281** 35747–35756. (<https://doi.org/10.1074/jbc.M604008200>)
- Choi JH & Yoo HW** 2013 Control of puberty: genetics, endocrinology, and environment. *Current Opinion in Endocrinology, Diabetes, and Obesity* **20** 62–68. (<https://doi.org/10.1097/MED.0b013e32835b7ec7>)
- Clarkson YL, McLaughlin M, Waterfall M, Dunlop CE, Skehel PA, Anderson RA & Telfer EE** 2018 Initial characterisation of adult human ovarian cell populations isolated by DDX4 expression and aldehyde dehydrogenase activity. *Scientific Reports* **8** 6953. (<https://doi.org/10.1038/s41598-018-25116-1>)
- Conway GS, Kaltsas G, Patel A, Davies MC & Jacobs HS** 1996 Characterization of idiopathic premature ovarian failure. *Fertility and Sterility* **65** 337–341. ([https://doi.org/10.1016/s0015-0282\(16\)58095-9](https://doi.org/10.1016/s0015-0282(16)58095-9))
- Cordts EB, Christofolini DM, Dos Santos AA, Bianco B & Barbosa CP** 2011 Genetic aspects of premature ovarian failure: a literature review. *Archives of Gynecology and Obstetrics* **283** 635–643. (<https://doi.org/10.1007/s00404-010-1815-4>)
- Coulam CB, Adamson SC & Annegers JF** 1986 Incidence of premature ovarian failure. *Obstetrics and Gynecology* **67** 604–606. (<https://doi.org/10.1097/00006254-198703000-00020>)
- Cox L & Liu JH** 2014 Primary ovarian insufficiency: an update. *International Journal of Women's Health* **6** 235–243. (<https://doi.org/10.2147/IJWH.S37636>)
- Craig ZR, Wang W & Flaws JA** 2011 Endocrine-disrupting chemicals in ovarian function: effects on steroidogenesis, metabolism and nuclear receptor signaling. *Reproduction* **142** 633–646. (<https://doi.org/10.1530/REP-11-0136>)
- de Cuevas M, Lilly MA & Spradling AC** 1997 Germline Cyst Formation in *Drosophila*. *Annual Review of Genetics* **31** 405–428. (<https://doi.org/10.1146/annurev.genet.31.1.405>)
- De Felici M, Klinger FG, Farini D, Scaldaferrri ML, Iona S & Lobascio M** 2005 Establishment of oocyte population in the fetal ovary: primordial germ cell proliferation and oocyte programmed cell death. *Reproductive Biomedicine Online* **10** 182–191. ([https://doi.org/10.1016/S1472-6483\(10\)60939-X](https://doi.org/10.1016/S1472-6483(10)60939-X))
- Demeestere I, Simon P, Dedeken L, Moffa F, Tsépélidis S, Brachet C, Delbaere A, Devreker F & Ferster A** 2015 Live birth after autograft of ovarian tissue cryopreserved during childhood. *Human Reproduction* **30** 2107–2109. (<https://doi.org/10.1093/humrep/dev128>)
- Depalo R, Nappi L, Loverro G, Bettocchi S, Caruso ML, Valentini AM & Selvaggi L** 2003 Evidence of apoptosis in human primordial and primary follicles. *Human Reproduction* **18** 2678–2682. (<https://doi.org/10.1093/humrep/deg507>)
- Ding X, Zhang X, Mu Y, Li Y & Hao J** 2013 Effects of BMP4/SMAD signaling pathway on mouse primordial follicle growth and survival via up-regulation of *Sohlh2* and *c-kit*. *Molecular Reproduction and Development* **80** 70–78. (<https://doi.org/10.1002/mrd.22138>)
- Ding Q, Chen Y, Zhang Q, Guo Y, Huang Z, Dai L & Cao S** 2015 8-bromo-7-methoxychrysin induces apoptosis by regulating Akt/FOXO3a pathway in cisplatin-sensitive and resistant ovarian cancer cells. *Molecular Medicine Reports* **12** 5100–5108. (<https://doi.org/10.3892/mmr.2015.4039>)
- Donnez J & Dolmans MM** 2017 Fertility preservation in women. *New England Journal of Medicine* **377** 1657–1665. (<https://doi.org/10.1056/NEJMr1614676>)
- Drummond AE** 2005 TGFβ signaling in the development of ovarian function. *Cell and Tissue Research* **322** 107–115. (<https://doi.org/10.1007/s00441-005-1153-1>)
- Dungan HM, Clifton DK & Steiner RA** 2006 Minireview: kisspeptin neurons as central processors in the regulation of gonadotropin-releasing hormone secretion. *Endocrinology* **147** 1154–1158. (<https://doi.org/10.1210/en.2005-1282>)
- Durlinger AL, Visser JA & Themmen AP** 2002 Regulation of ovarian function: the role of anti-Müllerian hormone. *Reproduction* **124** 601–609. (<https://doi.org/10.1530/rep.0.1240601>)
- Ebrahimi M & Akbari Asbagh F** 2015 The role of autoimmunity in premature ovarian failure. *Iranian Journal of Reproductive Medicine* **13** 461–472.
- Edson MA, Nagaraja AK & Matzuk MM** 2009 The mammalian ovary from genesis to revelation. *Endocrine Reviews* **30** 624–712. (<https://doi.org/10.1210/er.2009-0012>)
- Ernst EH, Grondahl ML, Grund S, Hardy K, Heuck A, Sunde L, Franks S, Andersen CY, Villesen P & Lykke-Hartmann K** 2017 Dormancy and activation of human oocytes from primordial and primary follicles: molecular clues to oocyte regulation. *Human Reproduction* **32** 1684–1700. (<https://doi.org/10.1093/humrep/dex238>)
- Ernst EH, Franks S, Hardy K, Villesen P & Lykke-Hartmann K** 2018 Granulosa cells from human primordial and primary follicles show differential global gene expression profiles. *Human Reproduction* **33** 666–679. (<https://doi.org/10.1093/humrep/dey011>)
- Estienne A, Pierre A, Di Clemente N, Picard JY, Jarrier P, Mansanet C, Monniaux D & Fabre S** 2015 Anti-Müllerian hormone regulation by the bone morphogenetic proteins in the sheep ovary: deciphering a direct regulatory pathway. *Endocrinology* **156** 301–313. (<https://doi.org/10.1210/en.2014-1551>)
- Faddy MJ, Gosden RG, Gougeon A, Richardson SJ & Nelson JF** 1992 Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. *Human Reproduction* **7** 1342–1346. (<https://doi.org/10.1093/oxfordjournals.humrep.a137570>)
- Fei M, Zhao Y, Wang Y, Lu M, Cheng C, Huang X, Zhang D, Lu J, He S & Shen A** 2009 Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. *Cancer Investigation* **27** 52–59. (<https://doi.org/10.1080/07357900802146204>)
- Findlay JK, Hutt KJ, Hickey M & Anderson RA** 2015 How is the number of primordial follicles in the ovarian reserve established? *Biology of Reproduction* **93** 111. (<https://doi.org/10.1095/biolreprod.115.133652>)
- Fisch B & Abir R** 2018 Female fertility preservation: past, present and future. *Reproduction* **156** F11–F27. (<https://doi.org/10.1530/REP-17-0483>)
- Fujihara M, Yamamizu K, Comizzoli P, Wildt DE & Songsasen N** 2018 Retinoic acid promotes in vitro follicle activation in the cat ovary by regulating expression of matrix metalloproteinase 9. *PLoS ONE* **13** e0202759. (<https://doi.org/10.1371/journal.pone.0202759>)
- Gannon AM, Stampfli MR & Foster WG** 2012 Cigarette smoke exposure leads to follicle loss via an alternative ovarian cell death pathway in a mouse model. *Toxicological Sciences* **125** 274–284. (<https://doi.org/10.1093/toxsci/kfr279>)
- Gaytan F, Morales C, Roa J & Tena-Sempere M** 2018 Changes in keratin 8/18 expression in human granulosa cell lineage are associated to cell death/survival events: potential implications for the maintenance of the ovarian reserve. *Human Reproduction* **33** 680–689. (<https://doi.org/10.1093/humrep/dey010>)
- Gellert SE, Pors SE, Kristensen SG, Bay-Bjørn AM, Ernst E & Yding Andersen C** 2018 Transplantation of frozen-thawed ovarian tissue: an update on worldwide activity published in peer-reviewed papers and on the Danish cohort. *Journal of Assisted Reproduction and Genetics* **35** 561–570. (<https://doi.org/10.1007/s10815-018-1144-2>)
- Georges A, Auguste A, Bessière L, Vanet A, Todeschini AL & Veitia RA** 2014 FOXL2: a central transcription factor of the ovary. *Journal of Molecular Endocrinology* **52** R17–R33. (<https://doi.org/10.1530/JME-13-0159>)
- Gorre N, Adhikari D, Lindkvist R, Brännström M, Liu K & Shen Y** 2014 mTORC1 signaling in oocytes is dispensable for the survival of primordial follicles and for female fertility. *PLoS ONE* **9** e110491. (<https://doi.org/10.1371/journal.pone.0110491>)
- Goswami D & Conway GS** 2005 Premature ovarian failure. *Human Reproduction Update* **11** 391–410. (<https://doi.org/10.1093/humupd/dmi012>)
- Goto M, Iwase A, Ando H, Kurotsuchi S, Harata T & Kikkawa F** 2007 PTEN and Akt expression during growth of human ovarian follicles. *Journal of Assisted Reproduction and Genetics* **24** 541–546. (<https://doi.org/10.1007/s10815-007-9156-3>)
- Gougeon A & Chainy GB** 1987 Morphometric studies of small follicles in ovaries of women at different ages. *Journal of Reproduction and Fertility* **81** 433–442. (<https://doi.org/10.1530/jrf.0.0810433>)
- Grabowska W, Sikora E & Bielak-Zmijewska A** 2017 Sirtuins, a promising target in slowing down the ageing process. *Biogerontology* **18** 447–476. (<https://doi.org/10.1007/s10522-017-9685-9>)
- Grive KJ & Freiman RN** 2015 The developmental origins of the mammalian ovarian reserve. *Development* **142** 2554–2563. (<https://doi.org/10.1242/dev.125211>)
- Grosbois J & Demeestere I** 2018 Dynamics of PI3K and Hippo signaling pathways during in vitro human follicle activation. *Human Reproduction* **33** 1705–1714. (<https://doi.org/10.1093/humrep/dey250>)
- Hannon PR & Flaws JA** 2015 The effects of phthalates on the ovary. *Frontiers in Endocrinology* **6** 8. (<https://doi.org/10.3389/fendo.2015.00008>)
- Hansen KR, Knowlton NS, Thyer AC, Charleston JS, Soules MR & Klein NA** 2008 A new model of reproductive aging: the decline in ovarian non-

- growing follicle number from birth to menopause. *Human Reproduction* **23** 699–708. (<https://doi.org/10.1093/humrep/dem408>)
- Hardy K, Mora JM, Dunlop C, Carzaniga R, Franks S & Fenwick MA 2018 Nuclear exclusion of SMAD2/3 in granulosa cells is associated with primordial follicle activation in the mouse ovary. *Journal of Cell Science* **131**. (<https://doi.org/10.1242/jcs.218123>)
- Henderson MA, Cronland E, Dunkelbarger S, Contreras V, Strome S & Keiper BD 2009 A germline-specific isoform of eIF4E (IFE-1) is required for efficient translation of stored mRNAs and maturation of both oocytes and sperm. *Journal of Cell Science* **122** 1529–1539. (<https://doi.org/10.1242/jcs.046771>)
- Himelstein-Braw R, Byskov AG, Peters H & Faber M 1976 Follicular atresia in the infant human ovary. *Journal of Reproduction and Fertility* **46** 55–59. (<https://doi.org/10.1530/jrf.0.0460055>)
- Hoek A, Schoemaker J & Drexhage HA 1997 Premature ovarian failure and ovarian autoimmunity. *Endocrine Reviews* **18** 107–134. (<https://doi.org/10.1210/edrv.18.1.0291>)
- Horan CJ & Williams SA 2017 Oocyte stem cells: fact or fantasy? *Reproduction* **154** R23–R35. (<https://doi.org/10.1530/REP-17-0008>)
- Hu LL, Su T, Luo RC, Zheng YH, Huang J, Zhong ZS, Nie J & Zheng LP 2019 Hippo pathway functions as a downstream effector of AKT signaling to regulate the activation of primordial follicles in mice. *Journal of Cellular Physiology* **234** 1578–1587. (<https://doi.org/10.1002/jcp.27024>)
- Huhtaniemi I, Hovatta O, La Marca A, Livera G, Monniaux D, Persani L, Heddar A, Jarzabek K, Laisk-Podar T, Salumets A *et al.* 2018 Advances in the molecular pathophysiology, genetics, and treatment of primary ovarian insufficiency. *Trends in Endocrinology and Metabolism* **29** 400–419. (<https://doi.org/10.1016/j.tem.2018.03.010>)
- Huntriss J, Hinkins M & Picton HM 2006 cDNA cloning and expression of the human NOBOX gene in oocytes and ovarian follicles. *Molecular Human Reproduction* **12** 283–289. (<https://doi.org/10.1093/molehr/gal035>)
- Ikeda Y, Hasegawa A, Tsubamoto H, Wakimoto Y, Kumamoto K & Shibahara H 2016 Effects of gremlin-2 on the transition of primordial follicles during early folliculogenesis in the human ovary. *European Journal of Obstetrics, Gynecology, and Reproductive Biology* **203** 72–77. (<https://doi.org/10.1016/j.ejogrb.2016.05.026>)
- Jin H, Won M, Park SE, Lee S, Park M & Bae J 2016 FOXL2 is an essential activator of SF-1-Induced transcriptional regulation of anti-Mullerian hormone in human granulosa cells. *PLoS ONE* **11** e0159112. (<https://doi.org/10.1371/journal.pone.0159112>)
- John GB, Gallardo TD, Shirley LJ & Castrillon DH 2008 Foxo3 is a PI3K-dependent molecular switch controlling the initiation of oocyte growth. *Developmental Biology* **321** 197–204. (<https://doi.org/10.1016/j.ydbio.2008.06.017>)
- Juriscova A, Taniuchi A, Li H, Shang Y, Antenos M, Detmar J, Xu J, Matikainen T, Benito Hernández A, Nunez G *et al.* 2007 Maternal exposure to polycyclic aromatic hydrocarbons diminishes murine ovarian reserve via induction of Harakiri. *Journal of Clinical Investigation* **117** 3971–3978. (<https://doi.org/10.1172/JCI28493>)
- Kalantaridou SN, Davis SR & Nelson LM 1998 Premature ovarian failure. *Endocrinology and Metabolism Clinics of North America* **27** 989–1006. ([https://doi.org/10.1016/S0889-8529\(05\)70051-7](https://doi.org/10.1016/S0889-8529(05)70051-7))
- Kallen A, Polotsky AJ & Johnson J 2018 Untapped reserves: controlling primordial follicle growth activation. *Trends in Molecular Medicine* **24** 319–331. (<https://doi.org/10.1016/j.molmed.2018.01.008>)
- Kawamura K, Cheng Y, Suzuki N, Deguchi M, Sato Y, Takae S, Ho CH, Kawamura N, Tamura M, Hashimoto S *et al.* 2013 Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment. *PNAS* **110** 17474–17479. (<https://doi.org/10.1073/pnas.1312830110>)
- Kim JY 2012 Control of ovarian primordial follicle activation. *Clinical and Experimental Reproductive Medicine* **39** 10–14. (<https://doi.org/10.5653/cerm.2012.39.1.10>)
- Knight PG & Glister C 2006 TGF- β superfamily members and ovarian follicle development. *Reproduction* **132** 191–206. (<https://doi.org/10.1530/rep.1.01074>)
- Komorowska B 2016 Autoimmune premature ovarian failure. *Przegląd Menopauzalny* **15** 210–214. (<https://doi.org/10.5114/pm.2016.65666>)
- Kristensen SG, Ebbesen P & Andersen CY 2015 Transcriptional profiling of five isolated size-matched stages of human preantral follicles. *Molecular and Cellular Endocrinology* **401** 189–201. (<https://doi.org/10.1016/j.mce.2014.12.012>)
- Lamb JD, Bloom MS, Vom Saal FS, Taylor JA, Sandler JR & Fujimoto VY 2008 Serum bisphenol A (BPA) and reproductive outcomes in couples undergoing IVF. *Fertility and Sterility* **90** S186. (<https://doi.org/10.1016/j.fertnstert.2008.07.751>)
- Lande Y, Fisch B, Tsur A, Farhi J, Prag-Rosenberg R, Ben-Haroush A, Kessler-Icekson G, Zahalka MA, Ludeman SM & Abir R 2017 Short-term exposure of human ovarian follicles to cyclophosphamide metabolites seems to promote follicular activation in vitro. *Reproductive Biomedicine Online* **34** 104–114. (<https://doi.org/10.1016/j.rbmo.2016.10.005>)
- Laronda MM, Duncan FE, Hornick JE, Xu M, Pahnke JE, Whelan KA, Shea LD & Woodruff TK 2014 Algininate encapsulation supports the growth and differentiation of human primordial follicles within ovarian cortical tissue. *Journal of Assisted Reproduction and Genetics* **31** 1013–1028. (<https://doi.org/10.1007/s10815-014-0252-x>)
- Lechowska A, Bilinski S, Choi Y, Shin Y, Kloc M & Rajkovic A 2011 Premature ovarian failure in nobox-deficient mice is caused by defects in somatic cell invasion and germ cell cyst breakdown. *Journal of Assisted Reproduction and Genetics* **28** 583–589. (<https://doi.org/10.1007/s10815-011-9553-5>)
- Lei L & Spradling AC 2016 Mouse oocytes differentiate through organelle enrichment from sister cyst germ cells. *Science* **352** 95–99. (<https://doi.org/10.1126/science.aad2156>)
- Lerer-Serfaty G, Samara N, Fisch B, Shachar M, Kossover O, Seliktar D, Ben-Haroush A & Abir R 2013 Attempted application of bioengineered/biosynthetic supporting matrices with phosphatidylinositol-trisphosphate-enhancing substances to organ culture of human primordial follicles. *Journal of Assisted Reproduction and Genetics* **30** 1279–1288. (<https://doi.org/10.1007/s10815-013-0052-8>)
- Lew R 2019 Natural history of ovarian function including assessment of ovarian reserve and premature ovarian failure. *Best Practice and Research: Clinical Obstetrics and Gynaecology* **55** 2–13. (<https://doi.org/10.1016/j.bpobgyn.2018.05.005>)
- Li L, Wang B, Zhang W, Chen B, Luo M, Wang J, Wang X, Cao Y & Kee K 2017 A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency. *Human Reproduction* **32** 248–255. (<https://doi.org/10.1093/humrep/dew271>)
- Maheshwari A & Fowler PA 2008 Primordial follicular assembly in humans – revisited. *Zygote* **16** 285–296. (<https://doi.org/10.1017/S0967199408004802>)
- Maidarti M, Clarkson YL, McLaughlin M, Anderson RA & Telfer EE 2019 Inhibition of PTEN activates bovine non-growing follicles in vitro but increases DNA damage and reduces DNA repair response. *Human Reproduction* **34** 297–307. (<https://doi.org/10.1093/humrep/dey354>)
- Makker A, Goel MM & Mahdi AA 2014 PI3K/PTEN/Akt and TSC/mTOR signaling pathways, ovarian dysfunction, and infertility: an update. *Journal of Molecular Endocrinology* **53** R103–R118. (<https://doi.org/10.1530/JME-14-0220>)
- Mamsen LS, Lutterodt MC, Andersen EW, Skouby SO, Sorensen KP, Andersen CY & Byskov AG 2010 Cigarette smoking during early pregnancy reduces the number of embryonic germ and somatic cells. *Human Reproduction* **25** 2755–2761. (<https://doi.org/10.1093/humrep/deq215>)
- Mamsen LS, Lutterodt MC, Andersen EW, Byskov AG & Andersen CY 2011 Germ cell numbers in human embryonic and fetal gonads during the first two trimesters of pregnancy: analysis of six published studies. *Human Reproduction* **26** 2140–2145. (<https://doi.org/10.1093/humrep/der149>)
- Man L, Park L, Bodine R, Ginsberg M, Zaninovic N, Schattman G, Schwartz RE, Rosenwaks Z & James D 2018 Co-transplantation of human ovarian tissue with engineered endothelial cells: a cell-based strategy combining accelerated perfusion with direct paracrine delivery. *Journal of Visualized Experiments* **135**. (<https://doi.org/10.3791/57472>)
- Manavella DD, Cacciottola L, Payen VL, Amorim CA, Donnez J & Dolmans MM 2019 Adipose tissue-derived stem cells boost vascularization in grafted ovarian tissue by growth factor secretion and differentiation into endothelial cell lineages. *Molecular Human Reproduction* **25** 184–193. (<https://doi.org/10.1093/molehr/gaz008>)
- Marcozzi S, Rossi V, Salustri A, De Felici M & Klinger FG 2018 Programmed cell death in the human ovary. *Minerva Ginecologica* **70** 549–560. (<https://doi.org/10.23736/S0026-4784.18.04274-0>)
- Margulis S, Abir R, Felz C, Nitke S, Krissi H & Fisch B 2009 Bone morphogenetic protein 15 expression in human ovaries from fetuses,

- girls, and women. *Fertility and Sterility* **92** 1666–1673. (<https://doi.org/10.1016/j.fertnstert.2008.08.119>)
- Mathew H & Mahalingaiah S** 2019 Do prenatal exposures pose a real threat to ovarian function? Bisphenol A as a case study. *Reproduction* **157** R143–R157. (<https://doi.org/10.1530/REP-17-0734>)
- Matsuda F, Inoue N, Manabe N & Ohkura S** 2012 Follicular growth and atresia in mammalian ovaries: regulation by survival and death of granulosa cells. *Journal of Reproduction and Development* **58** 44–50. (<https://doi.org/10.1262/jrd.2011-012>)
- Mcburney MW, Yang X, Jardine K, Hixon M, Boekelheide K, Webb JR, Lansdorp PM & Lemieux M** 2003 The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. *Molecular and Cellular Biology* **23** 38–54. (<https://doi.org/10.1128/mcb.23.1.38-54.2003>)
- McLaughlin M, Patrizio P, Kayisli U, Luk J, Thomson TC, Anderson RA, Telfer EE & Johnson J** 2011 mTOR kinase inhibition results in oocyte loss characterized by empty follicles in human ovarian cortical strips cultured in vitro. *Fertility and Sterility* **96** 1154–9.e1. (<https://doi.org/10.1016/j.fertnstert.2011.08.040>)
- McLaughlin M, Kinnell HL, Anderson RA & Telfer EE** 2014 Inhibition of phosphatase and tensin homologue (PTEN) in human ovary in vitro results in increased activation of primordial follicles but compromises development of growing follicles. *Molecular Human Reproduction* **20** 736–744. (<https://doi.org/10.1093/molehr/gau037>)
- McLaughlin M, Kelsey TW, Wallace WH, Anderson RA & Telfer EE** 2015 An externally validated age-related model of mean follicle density in the cortex of the human ovary. *Journal of Assisted Reproduction and Genetics* **32** 1089–1095. (<https://doi.org/10.1007/s10815-015-0501-7>)
- McLaughlin M, Kelsey TW, Wallace WH, Anderson RA & Telfer EE** 2017 Non-growing follicle density is increased following adriamycin, bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy in the adult human ovary. *Human Reproduction* **32** 165–174. (<https://doi.org/10.1093/humrep/dew260>)
- Motta PM, Makabe S & Nottola SA** 1997 The ultrastructure of human reproduction. I. The natural history of the female germ cell: origin, migration and differentiation inside the developing ovary. *Human Reproduction Update* **3** 281–295. (<https://doi.org/10.1093/humupd/3.3.281>)
- Muczynski V, Lecureuil C, Messiaen S, Guerquin MJ, N'tumba-Byn T, Moison D, Hodroj W, Benjelloun H, Baijjer J, Livera G et al.** 2012 Cellular and molecular effect of MEHP involving LXRalpha in human fetal testis and ovary. *PLoS ONE* **7** e48266. (<https://doi.org/10.1371/journal.pone.0048266>)
- Myers M, Morgan FH, Liew SH, Zerafa N, Gamage TU, Sarraj M, Cook M, Kapic I, Sutherland A, Scott CL et al.** 2014 PUMA regulates germ cell loss and primordial follicle endowment in mice. *Reproduction* **148** 211–219. (<https://doi.org/10.1530/REP-13-0666>)
- Nelson LM** 2009 Clinical practice. Primary ovarian insufficiency. *New England Journal of Medicine* **360** 606–614. (<https://doi.org/10.1056/NEJMc0808697>)
- Nguyen QN, Zerafa N, Liew SH, Findlay JK, Hickey M & Hutt KJ** 2019 Cisplatin- and cyclophosphamide-induced primordial follicle depletion is caused by direct damage to oocytes. *Molecular Human Reproduction* **020**. (<https://doi.org/10.1093/molehr/gaz020>)
- Oktay K, Nugent D, Newton H, Salha O, Chatterjee P & Gosden RG** 1997 Isolation and characterization of primordial follicles from fresh and cryopreserved human ovarian tissue. *Fertility and Sterility* **67** 481–486. ([https://doi.org/10.1016/s0015-0282\(97\)80073-8](https://doi.org/10.1016/s0015-0282(97)80073-8))
- Ono YJ, Tanabe A, Nakamura Y, Yamamoto H, Hayashi A, Tanaka T, Sasaki H, Hayashi M, Terai Y & Ohmichi M** 2014 A low-testosterone state associated with endometrioma leads to the apoptosis of granulosa cells. *PLoS ONE* **9** e115618. (<https://doi.org/10.1371/journal.pone.0115618>)
- Pangas SA, Choi Y, Ballow DJ, Zhao Y, Westphal H, Matzuk MM & Rajkovic A** 2006 Oogenesis requires germ cell-specific transcriptional regulators *Sohlh1* and *Lhx8*. *PNAS* **103** 8090–8095. (<https://doi.org/10.1073/pnas.0601083103>)
- Park M, Suh DS, Lee K & Bae J** 2014 Positive cross talk between *FOXL2* and anti-Müllerian hormone regulates ovarian reserve. *Fertility and Sterility* **102** 847.e1–855.e1. e841. (<https://doi.org/10.1016/j.fertnstert.2014.05.031>)
- Peck JD, Quaas AM, Craig LB, Soules MR, Klein NA & Hansen KR** 2016 Lifestyle factors associated with histologically derived human ovarian non-growing follicle count in reproductive age women. *Human Reproduction* **31** 150–157. (<https://doi.org/10.1093/humrep/dev271>)
- Pepling ME** 2006 From primordial germ cell to primordial follicle: mammalian female germ cell development. *Genesis* **44** 622–632. (<https://doi.org/10.1002/dvg.20258>)
- Pepling ME** 2016 DEVELOPMENT. Nursing the oocyte. *Science* **352** 35–36. (<https://doi.org/10.1126/science.aaf4943>)
- Persani L, Rossetti R, Cacciatore C & Bonomi M** 2009 Primary ovarian insufficiency: X chromosome defects and autoimmunity. *Journal of Autoimmunity* **33** 35–41. (<https://doi.org/10.1016/j.jaut.2009.03.004>)
- Persani L, Rossetti R, Di Pasquale E, Cacciatore C & Fabre S** 2014 The fundamental role of bone morphogenetic protein 15 in ovarian function and its involvement in female fertility disorders. *Human Reproduction Update* **20** 869–883. (<https://doi.org/10.1093/humupd/dmu036>)
- Peters H** 1969 The development of the mouse ovary from birth to maturity. *Acta Endocrinologica* **62** 98–116. (<https://doi.org/10.1530/acta.0.0620098>)
- Peters H, Byskov AG & Grinstead J** 1978 Follicular growth in fetal and prepubertal ovaries of humans and other primates. *Clinics in Endocrinology and Metabolism* **7** 469–485. ([https://doi.org/10.1016/S0300-595X\(78\)80005-X](https://doi.org/10.1016/S0300-595X(78)80005-X))
- Pierre A, Estienne A, Racine C, Picard JY, Fanchin R, Lahoz B, Alabart JL, Folch J, Jarrier P, Fabre S et al.** 2016 The bone morphogenetic protein 15 up-regulates the anti-Müllerian hormone receptor expression in granulosa cells. *Journal of Clinical Endocrinology and Metabolism* **101** 2602–2611. (<https://doi.org/10.1210/jc.2015-4066>)
- Podfigurna-Stopa A, Czyzyk A, Grymowicz M, Smolarczyk R, Katulski K, Czajkowski K & Meczekalski B** 2016 Premature ovarian insufficiency: the context of long-term effects. *Journal of Endocrinological Investigation* **39** 983–990. (<https://doi.org/10.1007/s40618-016-0467-z>)
- Qin Y, Jiao X, Dalgleish R, Vujovic S, Li J, Simpson JL, Al-Azzawi F & Chen ZJ** 2014 Novel variants in the *SOHLH2* gene are implicated in human premature ovarian failure. *Fertility and Sterility* **101** 1104.e6–1109.e6. (<https://doi.org/10.1016/j.fertnstert.2014.01.001>)
- Rajkovic A, Pangas SA, Ballow D, Suzumori N & Matzuk MM** 2004 NOBOX deficiency disrupts early folliculogenesis and oocyte-specific gene expression. *Science* **305** 1157–1159. (<https://doi.org/10.1126/science.1099755>)
- Ren Y, Suzuki H, Jagarlamudi K, Golnoski K, Mcguire M, Lopes R, Pachnis V & Rajkovic A** 2015 *Lhx8* regulates primordial follicle activation and postnatal folliculogenesis. *BMC Biology* **13** 39. (<https://doi.org/10.1186/s12915-015-0151-3>)
- Richardson MC, Guo M, Fauser BC & Macklon NS** 2014 Environmental and developmental origins of ovarian reserve. *Human Reproduction Update* **20** 353–369. (<https://doi.org/10.1093/humupd/dmt057>)
- Rodrigues P, Limback D, McGinnis LK, Plancha CE & Albertini DF** 2009 Multiple mechanisms of germ cell loss in the perinatal mouse ovary. *Reproduction* **137** 709–720. (<https://doi.org/10.1530/REP-08-0203>)
- Sacchi S, Marinaro F, Xella S, Marsella T, Tagliasacchi D & La Marca A** 2017 The anti-Müllerian hormone (AMH) induces forkhead box L2 (*FOXL2*) expression in primary culture of human granulosa cells in vitro. *Journal of Assisted Reproduction and Genetics* **34** 1131–1136. (<https://doi.org/10.1007/s10815-017-0980-9>)
- Schmidt D, Ovitte CE, Anlag K, Fehsenfeld S, Gredsted L, Treier AC & Treier M** 2004 The murine winged-helix transcription factor *Foxl2* is required for granulosa cell differentiation and ovary maintenance. *Development* **131** 933–942. (<https://doi.org/10.1242/dev.00969>)
- Schmidt KL, Kryger-Baggesen N, Byskov AG & Andersen CY** 2005 Anti-Müllerian hormone initiates growth of human primordial follicles in vitro. *Molecular and Cellular Endocrinology* **234** 87–93. (<https://doi.org/10.1016/j.mce.2004.12.010>)
- Schultz RM, Stein P & Svoboda P** 2018 The oocyte-to-embryo transition in mouse: past, present, and future. *Biology of Reproduction* **99** 160–174.
- Shapira M, Raanani H, Barshack I, Amariglio N, Derech-Haim S, Marciano MN, Schiff E, Orvieto R & Meirou D** 2018 First delivery in a leukemia survivor after transplantation of cryopreserved ovarian tissue, evaluated for leukemia cells contamination. *Fertility and Sterility* **109** 48–53. (<https://doi.org/10.1016/j.fertnstert.2017.09.001>)
- Shelling AN** 2010 Premature ovarian failure. *Reproduction* **140** 633–641. (<https://doi.org/10.1530/REP-09-0567>)
- Skory RM, Xu Y, Shea LD & Woodruff TK** 2015 Engineering the ovarian cycle using in vitro follicle culture. *Human Reproduction* **30** 1386–1395. (<https://doi.org/10.1093/humrep/dev052>)

- Smith MF, Mcintosh EW, Ricke WA, Kojima FN & Smith GW 1999 Regulation of ovarian extracellular matrix remodelling by metalloproteinases and their tissue inhibitors: effects on follicular development, ovulation and luteal function. *Journal of Reproduction and Fertility: Supplement* **54** 367–381. (<https://doi.org/10.1530/bioscioproc.4.029>)
- Steffensen LL, Ernst EH, Amoushahi M, Ernst E & Lykke-Hartmann K 2018 Transcripts encoding the androgen receptor and IGF-related molecules are differently expressed in human granulosa cells from primordial and primary follicles. *Frontiers in Cell and Developmental Biology* **6** 85. (<https://doi.org/10.3389/fcell.2018.00085>)
- Sugiura-Ogasawara M, Ozaki Y, Sonta S-I, Makino T & Suzumori K 2005 Exposure to bisphenol A is associated with recurrent miscarriage. *Human Reproduction* **20** 2325–2329. (<https://doi.org/10.1093/humrep/deh888>)
- Sun X, Su Y, He Y, Zhang J, Liu W, Zhang H, Hou Z, Liu J & Li J 2015 New strategy for in vitro activation of primordial follicles with mTOR and PI3K stimulators. *Cell Cycle* **14** 721–731. (<https://doi.org/10.1080/15384101.2014.995496>)
- Sun YC, Sun XF, Dyce PW, Shen W & Chen H 2017 The role of germ cell loss during primordial follicle assembly: a review of current advances. *International Journal of Biological Sciences* **13** 449–457. (<https://doi.org/10.7150/ijbs.18836>)
- Suzuki H, Kanai-Azuma M & Kanai Y 2015a From sex determination to initial folliculogenesis in mammalian ovaries: morphogenetic waves along the anteroposterior and dorsoventral axes. *Sexual Development* **9** 190–204. (<https://doi.org/10.1159/000440689>)
- Suzuki N, Yoshioka N, Takae S, Sugishita Y, Tamura M, Hashimoto S, Morimoto Y & Kawamura K 2015b Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. *Human Reproduction* **30** 608–615. (<https://doi.org/10.1093/humrep/deu353>)
- Tam PP & Snow MHL 1981 Proliferation and migration of primordial germ cells during compensatory growth in mouse embryos. *Journal of Embryology and Experimental Morphology* **64** 133–147.
- Tarnawa ED, Baker MD, Aloisio GM, Carr BR & Castrillon DH 2013 Gonadal expression of FoxO1, but not Foxo3, is conserved in diverse Mammalian species. *Biology of Reproduction* **88** 103. (<https://doi.org/10.1095/biolreprod.112.105791>)
- Tatone C, Di Emidio G, Barbonetti A, Carta G, Luciano AM, Falone S & Amicarelli F 2018 Sirtuins in gamete biology and reproductive physiology: emerging roles and therapeutic potential in female and male infertility. *Human Reproduction Update* **24** 267–289. (<https://doi.org/10.1093/humupd/dmy003>)
- Telfer EE & Fauser BC 2016 Important steps towards materializing the dream of developing an artificial ovary. *Reproductive Biomedicine Online* **33** 333–334. (<https://doi.org/10.1016/j.rbmo.2016.07.005>)
- Tilly JL 2001 Commuting the death sentence: how oocytes strive to survive. *Nature Reviews: Molecular Cell Biology* **2** 838–848. (<https://doi.org/10.1038/35099086>)
- Trisdale SK, Schwab NM, Hou X, Davis JS & Townson DH 2016 Molecular manipulation of keratin 8/18 intermediate filaments: modulators of FAS-mediated death signaling in human ovarian granulosa tumor cells. *Journal of Ovarian Research* **9** 8. (<https://doi.org/10.1186/s13048-016-0217-z>)
- Tsuiko O, Noukas M, Zilina O, Hensen K, Tapanainen JS, Magi R, Kals M, Kivistik PA, Haller-Kikkatalo K, Salumets A *et al.* 2016 Copy number variation analysis detects novel candidate genes involved in follicular growth and oocyte maturation in a cohort of premature ovarian failure cases. *Human Reproduction* **31** 1913–1925. (<https://doi.org/10.1093/humrep/dew142>)
- Uda M, Ottolenghi C, Crisponi L, Garcia JE, Deiana M, Kimber W, Forabosco A, Cao A, Schlessinger D & Pilia G 2004 Foxl2 disruption causes mouse ovarian failure by pervasive blockage of follicle development. *Human Molecular Genetics* **13** 1171–1181. (<https://doi.org/10.1093/hmg/ddh124>)
- Uhlenhaut NH & Treier M 2006 Foxl2 function in ovarian development. *Molecular Genetics and Metabolism* **88** 225–234. (<https://doi.org/10.1016/j.ymgme.2006.03.005>)
- Vachharajani VT, Liu T, Wang X, Hoth JJ, Yoza BK & McCall CE 2016 Sirtuins link inflammation and metabolism. *Journal of Immunology Research* **2016** 8167273. (<https://doi.org/10.1155/2016/8167273>)
- Van Der Stege JG, Groen H, Van Zadelhoff SJN, Lambalk CB, Braat DDM, Van Kasteren YM, Van Santbrink EJP, Apperloo MJ, Weijmar Schultz WC & Hoek A 2008 Decreased androgen concentrations and diminished general and sexual well-being in women with premature ovarian failure. *Menopause* **15** 23–31. (<https://doi.org/10.1097/gme.0b013e3180f6108c>)
- Visser JA & Themmen APN 2005 Anti-Müllerian hormone and folliculogenesis. *Molecular and Cellular Endocrinology* **234** 81–86. (<https://doi.org/10.1016/j.mce.2004.09.008>)
- Wang T, Brewer M & Zhu Q 2015 An overview of optical coherence tomography for ovarian tissue imaging and characterization. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology* **7** 1–16. (<https://doi.org/10.1002/wnan.1306>)
- Wang C, Cao J, Xing Y, Pu D, Liu J & Wu J 2016 TBP2 gene may not be associated with primary ovarian insufficiency. *Climacteric* **19** 565–567. (<https://doi.org/10.1080/13697137.2016.1231175>)
- Watkins WJ, Umbers AJ, Woad KJ, Harris SE, Winship IM, Gersak K & Shelling AN 2006 Mutational screening of FOXO3A and FOXO1A in women with premature ovarian failure. *Fertility and Sterility* **86** 1518–1521. (<https://doi.org/10.1016/j.fertnstert.2006.03.054>)
- Welt CK 2008 Primary ovarian insufficiency: a more accurate term for premature ovarian failure. *Clinical Endocrinology* **68** 499–509. (<https://doi.org/10.1111/j.1365-2265.2007.03073.x>)
- Winship AL, Bakai M, Sarma U, Liew SH & Hutt KJ 2018 Dacarbazine depletes the ovarian reserve in mice and depletion is enhanced with age. *Scientific Reports* **8** 6516. (<https://doi.org/10.1038/s41598-018-24960-5>)
- Woodruff TK & Shea LD 2011 A new hypothesis regarding ovarian follicle development: ovarian rigidity as a regulator of selection and health. *Journal of Assisted Reproduction and Genetics* **28** 3–6. (<https://doi.org/10.1007/s10815-010-9478-4>)
- Xiao S, Zhang J, Romero MM, Smith KN, Shea LD & Woodruff TK 2015 In vitro follicle growth supports human oocyte meiotic maturation. *Scientific Reports* **5** 17323. (<https://doi.org/10.1038/srep17323>)
- Zhai J, Yao G, Dong F, Bu Z, Cheng Y, Sato Y, Hu L, Zhang Y, Wang J, Dai S *et al.* 2016 In vitro activation of follicles and fresh tissue auto-transplantation in primary ovarian insufficiency patients. *Journal of Clinical Endocrinology and Metabolism* **101** 4405–4412. (<https://doi.org/10.1210/jc.2016-1589>)
- Zhang H & Liu K 2015 Cellular and molecular regulation of the activation of mammalian primordial follicles: somatic cells initiate follicle activation in adulthood. *Human Reproduction Update* **21** 779–786. (<https://doi.org/10.1093/humupd/dmv037>)
- Zhang H, Risal S, Gorre N, Busayavalasa K, Li X, Shen Y, Bosbach B, Brännström M & Liu K 2014 Somatic cells initiate primordial follicle activation and govern the development of dormant oocytes in mice. *Current Biology* **24** 2501–2508. (<https://doi.org/10.1016/j.cub.2014.09.023>)
- Zhang Y, Yan Z, Qin Q, Nisenblat V, Chang HM, Yu Y, Wang T, Lu C, Yang M, Yang S *et al.* 2018 Transcriptome landscape of human folliculogenesis reveals oocyte and granulosa cell interactions. *Molecular Cell* **72** 1021.e4–1034.e4. (<https://doi.org/10.1016/j.molcel.2018.10.029>)
- Zhou S, Yan W, Shen W, Cheng J, Xi Y, Yuan S, Fu F, Ding T, Luo A & Wang S 2018 Low expression of SEMA6C accelerates the primordial follicle activation in the neonatal mouse ovary. *Journal of Cellular and Molecular Medicine* **22** 486–496. (<https://doi.org/10.1111/jcmm.13337>)
- Zhou J, Peng X & Mei S 2019 Autophagy in ovarian follicular development and atresia. *International Journal of Biological Sciences* **15** 726–737. (<https://doi.org/10.7150/ijbs.30369>)

Received 6 May 2019

First decision 4 June 2019

Revised manuscript received 30 July 2019

Accepted 1 August 2019